Fenwick Represents OrsoBio in $67M Series B Funding

Fenwick represented OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, in its $67 million Series B funding. The round was co-led by Ascenta Capital and Woodline Partners LP with participation from existing investors Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, and Eli Lilly and Company.

OrsoBio will use the funds to accelerate development of the Company’s mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Bill Bromfield and included associates Leeza Soulina and Jing Liu.